Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders
The DOI matches its Crossref record; 281 of the 281 references it cites were found in a registry or an index.
Abstract
Epigenetic aberrations, which are recognized as key drivers of several human diseases, are often caused by genetic defects that result in functional deregulation of epigenetic proteins, their altered expression and/or their atypical recruitment to certain gene promoters. Importantly, epigenetic changes are reversible, and epigenetic enzymes and regulatory proteins can be targeted using small molecules. This Review discusses the role of altered expression and/or function of one class of epigenetic regulators--histone deacetylases (HDACs)--and their role in cancer, neurological diseases and immune disorders. We highlight the development of small-molecule HDAC inhibitors and their use in the laboratory, in preclinical models and in the clinic.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“There is increasing evidence that KDAC inhibitors work best in combination with other therapies [28–30]”
From Acetylation: a new target for protein degradation in cancer (2025) · cites this paper as [29]
In the citing paper
“Growing evidence supports that epigenetic dysregulation through histone deacetylases (HDACs) plays a critical role in synaptic dysfunction and memory loss in Alzheimer’s disease”
From CI-994 is a dual modulator of class I HDACs and Wnt/β-catenin signaling for the treatment of Alzheimer's disease (2026) · cites this paper as [4]
In the citing paper
“HDAC inhibitors can enhance histone acetylation and ameliorate cognitive impairments in various AD models, and HDAC inhibition has been recognized as an attractive therapeutic strategy for AD [4, 5, 7].”
From CI-994 is a dual modulator of class I HDACs and Wnt/β-catenin signaling for the treatment of Alzheimer's disease (2026) · cites this paper as [4]
In the citing paper
“HDAC inhibitors can enhance histone acetylation and ameliorate cognitive impairments in various AD models, and HDAC inhibition has been recognized as an attractive therapeutic strategy for AD [4, 5, 7].”
From CI-994 is a dual modulator of class I HDACs and Wnt/β-catenin signaling for the treatment of Alzheimer's disease (2026) · cites this paper as [4]
In the citing paper
“HDACs are epigenetic modulators that deacetylate lysine residues in histone and nonhistone substrates and their inhibition has attracted much interest for the treatment of neurodegenerative disorders, as several isoforms seem to be implicated in AD memory-related dysfunction: HDAC2 is a nuclear isoform that reduce transcription of CREB-regulated genes involved in learning and memory, HDAC6 targets”
From From combinations to multitarget-directed ligands: A continuum in Alzheimer’s disease polypharmacology (2021) · cites this paper as [118]
Citations
Cites
4 retracted
Zhang, X., Zhao, X., Fiskus, W., Lin, J., Lwin, T., Rao, R., Zhang, Y., Chan, J. C., Fu, K., Marquez, V. E., et al. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.09.003 · Cited by 276
RetractedChen, C.-S., Wang, Y.-C., Yang, H.-C., Huang, P.-H., Kulp, S. K., Yang, C.-C., Lu, Y.-S., Matsuyama, S., Chen, C.-Y., & Chen, C.-S. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-3996 · Cited by 187
RetractedDasmahapatra, G. P., Lembersky, D., Kramer, L. B., Fisher, R. I., Friedberg, J. W., Dent, P., & Grant, S. (2010) · Blood · doi:10.1182/blood-2009-12-257261 · Cited by 115
RetractedDasmahapatra, G. P., Lembersky, D., Son, M. P., Attkisson, E., Dent, P., Fisher, R. I., Friedberg, J. W., & Grant, S. (2011) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-10-1108 · Cited by 62
RetractedChromatin modifications and their function
Kouzarides, T. (2007) · Cell · doi:10.1016/j.cell.2007.02.005 · Cited by 10,883
Jaenisch, R., & Bird, A. (2003) · Nature Genetics · doi:10.1038/ng1089 · Cited by 6,325
Selective inhibition of BET bromodomains
Filippakopoulos, P., Qi, J., Picaud, S., Shen, Y., Smith, W. B., Fedorov, O., Morse, E. M., Keates, T., Hickman, T. T., Felletar, I., et al. (2010) · Nature · doi:10.1038/nature09504 · Cited by 4,262 · cited 3×
“AML1 and the AML1–ETO fusion protein in the pathogenesis of t(8;21) AML.”
BackgroundLysine acetylation targets protein complexes and co-regulates major cellular functions
Choudhary, C., Kumar, C., Gnad, F., Nielsen, M. L., Rehman, M., Walther, T. C., Olsen, J. V., & Mann, M. (2009) · Science · doi:10.1126/science.1175371 · Cited by 4,040
Immunogenic Cell Death in Cancer Therapy
Kroemer, G., Galluzzi, L., Kepp, O., & Zitvogel, L. (2013) · Annual Review of Immunology · doi:10.1146/annurev-immunol-032712-100008 · Cited by 3,303
Cancer epigenetics: from mechanism to therapy
Dawson, M. A., & Kouzarides, T. (2012) · Cell · doi:10.1016/j.cell.2012.06.013 · Cited by 3,203
Cited by
Items 801–900 of 1,003
Acetylation: a new target for protein degradation in cancer
Crawford, C. E. W., & Burslem, G. M. (2025) · Trends in Cancer · doi:10.1016/j.trecan.2025.01.013 · Cited by 20
Nishimoto, K., Niida, H., Uchida, C., Ohhata, T., Kitagawa, K., Motegi, A., Suda, T., & Kitagawa, M. (2020) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-20-0214 · Cited by 21
Zhu, J., Wang, F., Wang, L., Dai, B., Xu, G., Zhao, L., Jiang, H., Gao, W., Zhang, T., Zhao, C., et al. (2024) · Cancer Research · doi:10.1158/0008-5472.can-23-3250 · Cited by 26
Chen, Y., Zhang, L., Fang, L., Chen, C., Zhang, D., & Peng, T. (2024) · JACS Au · doi:10.1021/jacsau.4c00298 · Cited by 25
Histone deacetylases and inhibitors in diabetes mellitus and its complications
Wang, L., Bai, Y., Cao, Z., Guo, Z., Lian, Y., Liu, P., Zeng, Y., Lyu, W., & Chen, Q. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.117010 · Cited by 28
Alalhareth, I. S., Alyami, S. M., Alshareef, A. H., Ajeibi, A. O., Munjem, M. F. A., Elfifi, A. A., Alsharif, M. M., Alzahrani, S. A., Alqaad, M. A., Bakir, M. B., et al. (2025) · Pharmaceuticals · doi:10.3390/ph18020207 · Cited by 24
Gao, T., Sun, Y., Leng, P., Liu, D., Guo, Q., & Li, J. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1549520 · Cited by 34
Rondelet, G., & Wouters, J. (2017) · Biochimie · doi:10.1016/j.biochi.2017.06.003 · Cited by 22
Discovery of 1,3-Disubstituted 2,5-Diketopiperazine Derivatives as Potent Class I HDACs Inhibitors
Gong, G., Qi, J., Lv, Y., Dong, S., Cao, C., Li, D., Zhao, R. S., Li, Z., & Chen, X. (2020) · Chemical and Pharmaceutical Bulletin · doi:10.1248/cpb.c20-00056 · Cited by 20
Zwergel, C., Bello, E. D., Fioravanti, R., Conte, M., Nebbioso, A., Mazzone, R., Brosch, G., Mercurio, C., Varasi, M., Altucci, L., et al. (2020) · ChemMedChem · doi:10.1002/cmdc.202000854 · Cited by 24
Hsu, K., Chu, J.-C., Tseng, H.-J., Liu, C., Wang, H., Lin, T. E., Lee, H.-S., Hsin, L., Wang, A. H. ‐., Lin, C., et al. (2021) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2021.113419 · Cited by 22
Li, Y., Quan, J., Song, H., Li, D., Ma, E., Wang, Y., & Ma, C. (2021) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2021.105081 · Cited by 20
Geurs, S., Clarisse, D., Baele, F., Franceus, J., Desmet, T., Bosscher, K. D., & D’hooghe, M. (2022) · Chemical Communications · doi:10.1039/d2cc01550a · Cited by 20
Bello, E. D., Sian, V., Bontempi, G., Zwergel, C., Fioravanti, R., Noce, B., Castiello, C., Tomassi, S., Corinti, D., Passeri, D., et al. (2022) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2022.115022 · Cited by 20
Li, D., Zhang, Z., Li, Y., Wang, X., Zhong, H., Yang, H., Xi, Y., Liu, H., Shen, A., & Hu, Y. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c00525 · Cited by 20
Zhang, M., Dai, X., Xiang, Y., Xie, L., Sun, M., & Shi, J. (2023) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2023.115546 · Cited by 21
Radiotherapy-induced Immune Response Enhanced by Selective HDAC6 Inhibition
Noonepalle, S. K. R., Grindrod, S. C., Aghdam, N., Li, X., Gracia-Hernandez, M., Delgado, C. Z., Jung, M., Villagra, A., & Dritschilo, A. (2023) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-23-0215 · Cited by 21
Ding, Y., Wang, P., Li, C., Zhang, Y., Yang, C., Zhou, X., Wang, X., Su, Z., Ming, W., Zeng, L., et al. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241713474 · Cited by 22
“NaB can cause cell cycle arrest [1], inhibit the growth of cancer cells [2], and regulate energy metabolism and mitochondrial function [3].”
BackgroundEvolution of Slow-Binding Inhibitors Targeting Histone Deacetylase Isoforms
Mukherjee, A., Zamani, F., & Suzuki, T. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c01160 · Cited by 23
Chemical optogenetic modulation of inflammation and immunity
Parasar, B., & Chang, P. V. (2016) · Chemical Science · doi:10.1039/c6sc03702j · Cited by 21
Rompicharla, S. V. K., Trivedi, P., Kumari, P., Ghanta, P., Ghosh, B., & Biswas, S. (2016) · Nanomedicine · doi:10.2217/nnm-2016-0321 · Cited by 21
Hsiao, Y., Hung, H.-C., Yu, Y., Su, C.-L., Chen, S., & Gean, P. (2017) · Neurobiology of Learning and Memory · doi:10.1016/j.nlm.2017.02.020 · Cited by 20
Chuang, Y., Huang, S., Hsu, Y., Yu, M., Ou, G., Huang, W., & Hsu, M. (2017) · British Journal of Pharmacology · doi:10.1111/bph.13929 · Cited by 20
“There is also growing evidence indicating that HDAC inhibitors are effective at inducing cell cycle arrest and apoptosis in different types of human cancer cell lines, as well as disrupting angiogenesis (West and Johnstone, 2014) and suppressing tumour progression in preclinical models (Bolden et al., 2006; Falkenberg…”
BackgroundWon, H.-R., Ryu, H., Shin, D., Yeon, S.-K., Lee, D. H., & Kwon, S. H. (2018) · Molecular Carcinogenesis · doi:10.1002/mc.22852 · Cited by 21
“HDACi exhibits potent anticancer efficacy and activity in various other diseases, including neurological disorders, immune diseases, and metabolic disorders.(16) Despite the anticancer effects of specific HDACi against some cancer types, several aspects of HDAC and HDACi remain partially elucidated,”
BackgroundWu, C., Hsieh, Y., Murakami, M., Vahedi, S., Hsiao, S.-H., Yeh, N., Chou, A.-W., Li, Y., Wu, Y., Yu, J., et al. (2018) · Biochemical Pharmacology · doi:10.1016/j.bcp.2018.07.018 · Cited by 21
The hopeful anticancer role of oleuropein in breast cancer through histone deacetylase modulation
Mansouri, N., Alivand, M. R., Bayat, S., Khaniani, M. S., & Derakhshan, S. M. (2019) · Journal of Cellular Biochemistry · doi:10.1002/jcb.28965 · Cited by 20
“Because these processes are involved in malignancies, HDAC inhibitors are considered as a potent anticancer therapeutic tool.(49) Most of the five HDAC inhibitors including panobinostat, belinostat, chidamide, romidepsin, and suberoylanilide hydroxamic acid are Food and Drug Administration‐approved for the treatment o…”
BackgroundLiang, R., Zhang, J., Liu, Z., Liu, Z., Li, Q., Luo, X., Li, Y., Ye, J., & Lin, Y. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2020.585452 · Cited by 20
“Changes in HDAC inhibitors show promise as anticancer treatments (53, 54).”
BackgroundGlobal analysis of lysine acetylation in soybean leaves
Li, G., Zheng, B., Zhao, W., Ren, T., Zhang, X., Ning, T., & Liu, P. (2021) · Scientific Reports · doi:10.1038/s41598-021-97338-9 · Cited by 21
Hasegawa, H., Bissonnette, R. P., Gillings, M., Sasaki, D., Taniguchi, H., Kitanosono, H., Tsuruda, K., Kosai, K., Uno, N., Morinaga, Y., et al. (2016) · Cancer Science · doi:10.1111/cas.12971 · Cited by 21
Cao, K., Wang, H., Fang, Y., Wang, Y., Wei, L., Chen, X., Jiang, Z., Wei, X., & Hu, Y. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00870 · Cited by 20
USP7 deubiquitinates and stabilizes SIRT1.
Song, N., Cao, C., Tian, S., Long, M., & Liu, L. (2020) · The Anatomical Record · doi:10.1002/ar.24252 · Cited by 19
“Increasing experimental data show that the abnormal expression of HDACs is associated with a number of malignancies (Haberland et al., 2009; Falkenberg and Johnstone, 2014).”
BackgroundHDAC3 as an Emerging Therapeutic Target for Alzheimer's Disease and other Neurological Disorders
Li, Y., Izhar, T., & Kanekiyo, T. (2025) · Molecular Neurobiology · doi:10.1007/s12035-025-04866-w · Cited by 22
“The histone acetylation plays a critical role in the epigenetic regulation of gene expression and is associated with synaptic plasticity and cognitive function [6–9].”
InfluentialKashyap, K., & Kakkar, R. (2019) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2019.1567388 · Cited by 20
“Naturally, deregulation of HDACs results in various cancers, neuropathological, inflammatory and parasitic diseases (Falkenberg & Johnstone, 2014; Zwergel, Stazi, Valente & Mai, 2016).”
BackgroundAdvances in glioma-associated oncogene (GLI) inhibitors for cancer therapy
Zhang, M., Gao, L., Ye, Y., & Li, X. (2021) · Investigational New Drugs · doi:10.1007/s10637-021-01187-2 · Cited by 19
“Currently, HDACis can be classified as hydroxamic acid-based, cyclic tetra/depsipeptides, amino–benzamide-based, short-chain fatty acid-derived [85] or hydrazide-based [86, 87].”
BackgroundXiang, X., Dong, G., Zhu, J., Zhang, G., & Dong, Z. (2021) · Clinical Science · doi:10.1042/cs20210823 · Cited by 19
Yu, B., Liu, L., Cai, F., Peng, Y., Tang, X., Zeng, D., Li, T., Zhang, F., Liang, Y., Yuan, X., et al. (2022) · Cancer Cell International · doi:10.1186/s12935-022-02443-y · Cited by 19
“Therefore, WT-161, an HDAC6 inhibitor, has emerged as a promising anticancer agent [17, 18].”
BackgroundHuê, B. T. B., Nguyen, P. H., Quân, P. M., Tran, H. P., Tran, Q. D., Jung, H., Hong, Q. V., Nguyễn, C. Q., Nguyen, Q. P., Le, H. T., et al. (2022) · Molecules · doi:10.3390/molecules27072204 · Cited by 19
“However, most hydroxamates are pan-HDACIs that act on all HDAC classes with several obvious side effects including fatigue, thrombo-cytopenia and gastrointestinal issues [12,13], and isoform selective HDACIs may possess a better therapeutic index and fewer adverse effects [14–16].”
BackgroundWang, L., Sun, T., Wang, Z., Liu, H., Qiu, W., Tang, X., Guo, H., Yang, P., Yao, C., & Sun, H. (2023) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.3c00358 · Cited by 20
Zhang, K., Huang, R., Ji, M., Lin, S., Lai, F., Wu, D., Tian, H., Bi, J., Peng, S., Hu, J., et al. (2023) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2023.116015 · Cited by 20
Terri, M., Sandoval, P., Bontempi, G., Montaldo, C., Tomero‐Sanz, H., de Turris, V., Trionfetti, F., Pascual‐Antón, L., Clares, I., Battistelli, C., et al. (2024) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-023-02930-8 · Cited by 21
“Indeed, histone deacetylases have crucial roles in cancer cells where they are often overexpressed, increasing proliferation, and causing cell de-differentiation [19–21].”
BackgroundLiu, Y., Lee, H., Lai, M.-J., Pan, S., Huang, H.-L., Kuo, F.-C., Chen, M.-C., & Liou, J. (2015) · Organic & Biomolecular Chemistry · doi:10.1039/c5ob01509j · Cited by 19
Manipulation of the host protein acetylation network by human immunodeficiency virus type 1.
Jeng, M. Y., Ali, I., & Ott, M. (2015) · PubMed · doi:10.3109/10409238.2015.1061973 · Cited by 22
Epigenetics in Personalized Management of Lung Cancer
Ahmad, A. (2015) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-24932-2_6 · Cited by 19
Clinical Interventions in HIV Cure Research
Rasmussen, T. A., & Søgaard, O. S. (2018) · Advances in experimental medicine and biology · doi:10.1007/978-981-13-0484-2_12 · Cited by 22
Zhang, S., Tang, Z., Qing, B., Tang, R., Duan, Q., Ding, S., & Deng, D. (2019) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2019.172745 · Cited by 23
Ice, R. J., Chen, M. M., Sidorov, M., Ho, T. L., Woo, R. W. L., Rodriguez-Brotons, A., Luu, T., Jian, D., Kim, K. B., Leong, S. P. L., et al. (2019) · British Journal of Cancer · doi:10.1038/s41416-019-0696-y · Cited by 22
Acetylation dependent functions of Rab22a-NeoF1 Fusion Protein in Osteosarcoma
Liang, X., Wang, X., He, Y., Wu, Y., Zhong, L., Liu, W., Liao, D., & Kang, T. (2020) · Theranostics · doi:10.7150/thno.46082 · Cited by 19
“HDACis like vorinostat, belinostat, panobinostat, romidepsin, valproic acid and sodium butyrate have been approved by FDA for the treatment of cutaneous T cell lymphoma, peripheral T cell lymphoma, multiple myeloma or neurological disorders [30, 32, 33].”
BackgroundDiscovery of a Novel Hybrid of Vorinostat and Riluzole as a Potent Antitumor Agent
Xu, Q., Liu, C., Zang, J., Gao, S., Chou, C. J., & Zhang, Y. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.00454 · Cited by 18
“Generally, HDAC overexpression causes a low histone acetylation level, which can downregulate the expression of many genes, including tumor suppressor genes, leading to cancer (Falkenberg and Johnstone, 2014).”
BackgroundPreclinical Advances in Theranostics for the Different Molecular Subtypes of Breast Cancer
Fang, H., Cavaliere, A., Li, Z., Huang, Y. H., & Marquez-Nostra, B. V. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.627693 · Cited by 20
“Histone Deacetylases Histone deacetylases (HDACs) are a class of enzymes that modulate transcription and therefore alter gene expression (Bolden et al., 2006; Falkenberg and Johnstone, 2014).”
BackgroundGünel, N. S., Birden, N., Kurt, C. Ç., Bağca, B. G., Shademan, B., Söğütlü, F., Özateş, N. P., & Avci, Ç. B. (2021) · Molecular Biology Reports · doi:10.1007/s11033-021-06616-2 · Cited by 19
Sattar, R. S. A., Sumi, M. P., Nimisha, Apurva, A., Kumar, A., Sharma, A. K., Ahmad, E., Ali, A., Mahajan, B., & Saluja, S. S. (2021) · Cellular Signalling · doi:10.1016/j.cellsig.2021.110080 · Cited by 20
The intestinal epithelial cell cycle: uncovering its ‘cryptic’ nature
McKernan, D. P., & Egan, L. J. (2015) · Current Opinion in Gastroenterology · doi:10.1097/mog.0000000000000154 · Cited by 19
Histone deacetylase 6 activity is critical for the metastasis of Burkitt’s lymphoma cells
Ding, N., Ping, L., Feng, L., Zheng, X., Song, Y., & Zhu, J. (2014) · Cancer Cell International · doi:10.1186/s12935-014-0139-z · Cited by 20
Meng, Q., Yang, G., Yu, Y. W., Ding, F., & Hu, F. (2020) · PubMed · Cited by 26
Yuan, Y., Hu, Z., Bao, M., Sun, R., Long, X., Li, L., Li, J., Wu, C., & Bao, J. (2018) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2018.1541141 · Cited by 18
“So far, there are several major classes of HDAC inhibitors (HDACI) including hydroxamic-acid-based, cyclic-tetra/depsipeptide-based, amino-benzamide-based, and short-chainfatty-acid-derived (Falkenberg & Johnstone, 2014).”
BackgroundGil, M., González, R., Vázquez-Calvo, Á., Álvarez‐Gutiérrez, A., Martín-Acebes, M. A., Praena, B., Bello‐Morales, R., Sáiz, J., López‐Guerrero, J. A., Tabarés, E., et al. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8091442 · Cited by 19
Wu, S., Wang, L., Sun, H. B., Wang, W., & Yu, Y. X. (2020) · SAR and QSAR in environmental research · doi:10.1080/1062936x.2020.1777584 · Cited by 19
Sun, Q., Dai, Q., Zhang, C., Chen, Y., Zhao, L., Yuan, Z., & Jiang, Y. (2021) · Chinese Chemical Letters · doi:10.1016/j.cclet.2021.02.004 · Cited by 18
Tumorigenic effect of TERT and its potential therapeutic target in NSCLC (Review)
Liu, Y., Li, N., Wang, M., Yan-hua, Z., Yan, L.-D., Zhou, W., Yu, Z.-Q., Peng, X., & Cai, J. (2021) · Oncology Reports · doi:10.3892/or.2021.8133 · Cited by 20
Li, G., Li, D., Yuan, F., Cheng, C., Chen, L., & Wei, X. (2021) · Annals of Translational Medicine · doi:10.21037/atm-21-5066 · Cited by 18
Evaluation of the antioxidative and genotoxic effects of sodium butyrate on breast cancer cells
Yüksel, B., Özkan, A. D., Aydın, D., & Betts, Z. (2022) · Saudi Journal of Biological Sciences · doi:10.1016/j.sjbs.2021.12.061 · Cited by 20
Li, J., Yu, C., Shen, F., Cui, B., Liu, N., & Zhuang, S. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.946192 · Cited by 23
“HDACs are a group of enzymes that induce global changes in gene transcription and protein expression through removal of acetyl groups from histone and non-histone proteins (Falkenberg and Johnstone, 2014; Zhao et al., 2018).”
BackgroundStudying Chromatin Epigenetics with Fluorescence Microscopy
Stepanov, A. I., Беседовская, З. В., Moshareva, M. A., Lukyanov, K. A., & Putlyaeva, L. V. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23168988 · Cited by 19
“They focused on the detection of the H3K9ac modification, a mark that is found to be involved in diseases as serious as Alzheimer’s disease [59], autism spectrum disorder [60] as well as several cancers [61,62].”
BackgroundAR-regulated ZIC5 contributes to the aggressiveness of prostate cancer
Tan, Y.-F., Zhang, Y., Ge, S., Zhong, F., Sun, C., & Xia, G. (2022) · Cell Death Discovery · doi:10.1038/s41420-022-01181-4 · Cited by 19
“Histone deacetylases (HDACs), which remove acetyl groups from histone tail lysine residues, trigger a more condensed chromatin structure, resulting in gene repression [60].”
BackgroundZhao, L., Liang, Q., He, Y., Liu, M., Tong, R., Jiang, Z., Wang, W., & Shi, J. (2022) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2022.106181 · Cited by 18
Drzewiecka, M., Gajos-Michniewicz, A., Hoser, G., Jaśniak, D., Barszczewska-Pietraszek, G., Sitarek, P., Czarny, P. L., Piekarski, J. H., Radek, M., Czyż, M., et al. (2023) · Genes · doi:10.3390/genes14061295 · Cited by 20
Ribosomal frameshifting at normal codon repeats recodes functional chimeric proteins in human
Ren, G., Gu, X., Zhang, L., Gong, S., Song, S., Chen, S., Chen, Z., Wang, X., Li, Z., Zhou, Y., et al. (2024) · Nucleic Acids Research · doi:10.1093/nar/gkae035 · Cited by 22
Combretastatin A-4 based compounds as potential anticancer agents: A review
Omar, M. H., Emam, S. H., Mikhail, D. S., & Elmeligie, S. E. (2024) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2024.107930 · Cited by 23
Henderson, S. E., Ding, L.-Y., Mo, X. M., Bekaii‐Saab, T., Kulp, S. K., Chen, C., & Huang, P.-H. (2016) · Neoplasia · doi:10.1016/j.neo.2016.10.003 · Cited by 21
Chirichella, M., Lisi, S., Fantini, M., Goracci, M., Calvello, M., Brandi, R., Arisi, I., D’Onofrio, M., Primio, C. D., & Cattaneo, A. (2017) · Nature Methods · doi:10.1038/nmeth.4144 · Cited by 18
Good, K., de Paz, A. M., Tyagi, M. V., Cheema, M. S., Thambirajah, A. A., Gretzinger, T. L., Stefanelli, G., Chow, R. L., Krupke, O. A., Hendzel, M. J., et al. (2017) · Epigenetics · doi:10.1080/15592294.2017.1380760 · Cited by 15
Nardilysin controls intestinal tumorigenesis through HDAC1/p53–dependent transcriptional regulation
Kanda, K., Sakamoto, J., Matsumoto, Y., Ikuta, K., Goto, N., Morita, Y., Ohno, M., Nishi, K., Eto, K., Kimura, Y., et al. (2018) · JCI Insight · doi:10.1172/jci.insight.91316 · Cited by 17
Zhou, X., Liu, Z., Wang, H., Liu, X., Zhou, Z., Tang, J., Liu, X., Zheng, M., & Shen, Y. (2018) · Journal of drug targeting · doi:10.1080/1061186x.2018.1519028 · Cited by 18
“tumours at doses well tolerated by patients [16,17].”
BackgroundStoddard, S. V., May, X., Rivas, F., Dodson, K., Vijayan, S. M., Adhika, S., Parker, K., & Watkins, D. L. (2018) · Molecular Informatics · doi:10.1002/minf.201800080 · Cited by 18
Liang, H., Wang, Q., Wang, D., Zheng, H., Kalvakolanu, D. V., Lu, H., Wen, N., Chen, X., Xu, L., Ren, J., et al. (2020) · Biochemical Pharmacology · doi:10.1016/j.bcp.2020.114118 · Cited by 19
Nencetti, S., Cuffaro, D., Nuti, E., Ciccone, L., Rossello, A., Fabbi, M., Ballante, F., Ortore, G., Carbotti, G., Campelli, F., et al. (2020) · Journal of Enzyme Inhibition and Medicinal Chemistry · doi:10.1080/14756366.2020.1835883 · Cited by 19
Hepigenetics: A Review of Epigenetic Modulators and Potential Therapies in Hepatocellular Carcinoma
Yousef, M. H., El‐Fawal, H. A. N., & Abdelnaser, A. (2020) · BioMed Research International · doi:10.1155/2020/9593254 · Cited by 18
“There are around 18 HDACs, many of which have been shown to deacetylate nonhistone proteins [63].”
BackgroundGuillebon, É. D., Jimenez, M., Mazzarella, L., Betsou, F., Stadler, P. F., Peták, I., Jeannot, E., Chanas, L., Servant, N., Marret, G., et al. (2021) · ESMO Open · doi:10.1016/j.esmoop.2021.100106 · Cited by 23
“Finally, some HDACs, in particular HDAC9, regulate the expression of FOXP3, the master transcription factor in regulatory T cells (Tregs).(43) In mice, a decrease in Tregmediated immunosuppression was observed in non-smallcell lung cancer (NSCLC) under treatment with HDACi and a bromodomain inhibitor, which belongs to…”
BackgroundHuang, Z., Cai, L., & Tu, B. P. (2015) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2015.05.004 · Cited by 20
A phase I study of resminostat in Japanese patients with advanced solid tumors
Kitazono, S., Fujiwara, Y., Nakamichi, S., Mizugaki, H., Nokihara, H., Yamamoto, N., Yamada, Y., Inukai, E., Nakamura, O., & Tamura, T. (2015) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-015-2741-8 · Cited by 18
Jadhavar, P. S., Ramachandran, S. A., Riquelme, E., Gupta, A., Quinn, K. P., Shivakumar, D. M., Ray, S. S., Zende, D., Nayak, A. K., Miglani, S. K., et al. (2016) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2016.09.058 · Cited by 18
BET Proteins: An Approach to Future Therapies in Transplantation
Suárez-Álvarez, B., Rodríguez, R. M. A., Ruiz‐Ortega, M., & López‐Larrea, C. (2017) · American Journal of Transplantation · doi:10.1111/ajt.14221 · Cited by 19
“The addition of an acetyl group to histones is catalyzed by histone acetyltransferases (“writer” proteins), whereas histone deacetylases (“eraser” proteins) are responsible for removing these epigenetic marks (6).”
BackgroundSaito, K., Funayama, T., Yokota, Y., Murakami, T., & Kobayashi, Y. (2017) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.b16-01025 · Cited by 18
Isophthalic Acid‐Based HDAC Inhibitors as Potent Inhibitors of HDAC8 from Schistosoma mansoni
Stenzel, K., Chakrabarti, A., Melesina, J., Hansen, F. K., Lancelot, J., Herkenhöhner, S., Lungerich, B., Marek, M., Romier, C., Pierce, R. J., et al. (2017) · Archiv der Pharmazie · doi:10.1002/ardp.201700096 · Cited by 19
Molecular Mechanisms of Epigenetic Regulators as Activatable Targets in Cancer Theranostics
Li, Y., Li, Z., & Zhu, W. (2019) · Current Medicinal Chemistry · doi:10.2174/0929867324666170921101947 · Cited by 21
Biosynthesis of histone messenger RNA employs a specific 3' end endonuclease
Pettinati, I., Grzechnik, P., de Almeida, C. R., Brem, J., McDonough, M. A., Dhir, S., Proudfoot, N. J., & Schofield, C. J. (2018) · eLife · doi:10.7554/elife.39865 · Cited by 16
Xu, W., Xu, B., Yao, Y., Yu, X., & Shen, J. (2015) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2015.05.078 · Cited by 18
Romidepsin and the Zinc‐Binding Thiol Family of Natural Product HDAC Inhibitors
Ganesan, A. (2016) · Wiley eBooks · doi:10.1002/9783527800315.ch2 · Cited by 18
An epi(c)genetic war: Pathogens, cancer and human genome
Rajagopalan, D., & Jha, S. (2018) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2018.04.003 · Cited by 20
Rodgers, L. T., McCully, C. L., Odabas, A., Cruz, R., Peer, C. J., Figg, W. D., & Warren, K. E. (2020) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-019-04021-y · Cited by 17
Implication of epigenetic factors in the pathogenesis of type 1 diabetes
Zhang, J., Chen, L., Zou, Y., Zhang, S., Xiong, F., & Wang, C. (2021) · Chinese Medical Journal · doi:10.1097/cm9.0000000000001450 · Cited by 24
Abdel-Atty, M. M., Farag, N. A., Serya, R. A. T., Abouzid, K. A. M., & Mowafy, S. (2021) · Journal of Enzyme Inhibition and Medicinal Chemistry · doi:10.1080/14756366.2021.1933465 · Cited by 17
“The cyclisation of (1) into (2) was achieved through refluxing (1) in a mixture of formamide and acetic acid for 40 h.”
BackgroundMethodInfluentialGu, X. Q., Zhang, H., Jiao, M.-R., Han, B. R., Zhang, Z., Li, J., & Zhang, Q. (2021) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2021.114090 · Cited by 19
Porcine Deltacoronavirus Infection Cleaves HDAC2 to Attenuate Its Antiviral Activity
Li, Z., Fang, P., Duan, P., Chen, J., Fang, L., & Xiao, S. (2022) · Journal of Virology · doi:10.1128/jvi.01027-22 · Cited by 22
“Overexpression of HDAC11 exhibits stronger inhibitory effects on IAV and hepatitis B virus (HBV) by inducing ISG expression; however, IAV antagonizes the antiviral activity of HDAC11 by downregulating its expression in host cells (62, 63).”
BackgroundInfluentialKawamura, Y., Hua, L., Gurtner, A., Wong, E., Kiyokawa, J., Shah, N., Gorham, J., Wakimoto, H., Rabkin, S. D., Martuza, R. L., et al. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.113843 · Cited by 19
“HDAC is a group of epigenome modifying enzymes that are highly expressed in neoplastic cells and play a vital role in a variety of processes including gene expression regulation, cell survival, proliferation, and immune responses [26].”
Wang, M.-Q., Zhu, J., Ye, Y.-Q., Li, P., Sun, W.-J., & Zhang, M. (2023) · Aging · doi:10.18632/aging.204868 · Cited by 17
Dysregulation of histone deacetylases in ocular diseases
Jun, J. H., Kim, J.-S., Palomera, L. F., & Jo, D. (2023) · Archives of Pharmacal Research · doi:10.1007/s12272-023-01482-x · Cited by 19
Budzyński, M. A., Crul, T., Himanen, S. V., Tóth, N., Ötvös, F., Sistonen, L., & Vígh, L. (2017) · Cell Stress and Chaperones · doi:10.1007/s12192-017-0798-5 · Cited by 18
Stenzel, K., Chua, M. J., Duffy, S., Antonova‐Koch, Y., Meister, S., Hamacher, A., Kassack, M. U., Winzeler, E. A., Avery, V. M., Kurz, T., et al. (2017) · ChemMedChem · doi:10.1002/cmdc.201700360 · Cited by 19
Cramer, S., Miller, A. L., Pressey, J. G., Gamblin, T. L., Beierle, E. A., Kulbersh, B. D., Garcia, P. L., Radhakrishnan, R., Hendrix, S. V., Kelly, D. R., et al. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2017.00327 · Cited by 18
Metadata
- Authors
- Falkenberg, K. J., & Johnstone, R. W.
- Affiliations
- Peter MacCallum Cancer Centre (AU)
- The University of Melbourne (AU)
- Corresponding author
- Johnstone, Ricky W.
- ORCID
- Johnstone, Ricky W.
- Venue
- Nature Reviews Drug Discovery
- Published
- 2014-08-18
- Volume
- 13
- Issue
- 9
- Pages
- 673-691
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W2046345187
- Cited by
- 1,564
- References
- 281
- Citations by year
- 2026: 82 · 2025: 110 · 2024: 89 · 2023: 96 · 2022: 121 · 2021: 133 · 2020: 160 · 2019: 146 · 2018: 134 · 2017: 166 · 2016: 208 · 2015: 108 · 2014: 8
- FWCI
- 15.82
- Type
- journal article
- Language
- en
- Update notices
- addendum (2015-02-27)
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Nature Reviews Drug Discovery (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Histone Deacetylase Inhibitors Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Epigenetics and DNA Methylation
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Genomics and Chromatin Dynamics
- Keywords
- histone deacetylase, histone deacetylase inhibitors, epigenetic regulation, cancer, neurological disorders, immune disorders, small molecule inhibitors, lysine deacetylation, epigenetic aberrations, drug development
- MeSH terms
- Animals, Histone Deacetylases, Humans, Immune System Diseases, Neoplasms, Nervous System Diseases, Epigenesis, Genetic, Histone Deacetylase Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.